Clinical Trial Update: Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease [Phase 2]

View source ↗

Summary

Phase 2 within-subject crossover trial of neflamapimod in early-stage Huntington disease; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Neflamapimod (neflamapimod)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Huntington Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-04-06